Paris, France | January 22, 2026 — PulseSight Therapeutics, a Paris-based clinical-stage biotechnology company, has announced the successful completion of dosing and enrolment in its Phase I clinical trial of PST-611, an investigational non-viral vectorized gene therapy for dry Age-related Macular Degeneration (AMD) and Geographic Atrophy (GA). The study, conducted across two French clinical centers, evaluated safety and tolerability in six patients across two dose cohorts, marking a critical early milestone in the program’s clinical development. Top-line data are expected to be presented at the 2026 ARVO Annual Meeting (May 3–7), reinforcing the company’s progress toward addressing one of ophthalmology’s most significant unmet medical needs.
Science Significance
The completion of dosing represents an important scientific advancement for PST-611, a first-in-class therapy expressing human transferrin, a natural protein involved in iron homeostasis. In dry AMD and GA, dysregulated iron metabolism leads to oxidative stress, inflammation, and ferroptosis-driven retinal cell death. By restoring iron balance, PST-611 aims to protect photoreceptors and retinal pigment epithelium (RPE) cells, preserving visual function. Preclinical studies have demonstrated retinal protection and sustained biological activity, while the Phase I study now establishes foundational human safety data. The use of electro-transfection to deliver DNA plasmids into the ciliary muscle is scientifically significant, as it enables long-lasting protein expression with minimally invasive administration.
Regulatory Significance
From a regulatory perspective, the Phase I trial aligns with Good Clinical Practice (GCP) standards and represents the first-in-human evaluation of PST-611. Completion of enrolment without reported safety issues positions the program for Phase IIa readiness, an essential step toward dose optimization and early efficacy assessment. The study’s execution at leading academic hospitals in Paris and Grenoble further strengthens its regulatory credibility. Successful Phase I completion is a key prerequisite for continued regulatory engagement, supporting future interactions with European and global health authorities as the program advances.
Business Significance
Advertisement
For PulseSight Therapeutics, this milestone significantly de-risks the PST-611 asset and enhances its overall pipeline value. Dry AMD and GA represent a large and growing commercial market, with global AMD prevalence exceeding 200 million patients and limited treatment options for the dry form. By advancing a non-viral, repeat-dose-friendly gene therapy platform, PulseSight differentiates itself within a competitive ophthalmology landscape dominated by biologics and invasive approaches. Progress toward Phase IIa also strengthens the company’s positioning with current investors and potential strategic partners, supporting long-term value creation.
Patients’ Significance
For patients, particularly the elderly population affected by GA, the announcement carries meaningful hope. Late-stage dry AMD currently lacks approved therapies that can halt or reverse disease progression, often resulting in irreversible central vision loss. PST-611’s potential for sustained activity with re-treatment only every four to six months could significantly reduce treatment burden while preserving vision-related quality of life. If clinical efficacy is confirmed, PST-611 may emerge as a transformative option for patients who currently face inevitable visual decline.
Policy Significance
At a policy level, the development of PST-611 aligns with broader healthcare priorities focused on addressing age-related diseases, reducing disability, and managing the socioeconomic burden of vision loss. Innovative therapies that delay or prevent blindness can reduce long-term healthcare costs and dependency. Additionally, the success of non-viral gene therapy platforms may influence future regulatory and funding policies aimed at supporting safer, more scalable genetic medicines within Europe and beyond.
The completion of Phase I dosing for PST-611 marks a pivotal step in the clinical translation of PulseSight Therapeutics’ innovative gene therapy platform. With safety and tolerability now established in humans, the program is well positioned to advance into Phase IIa development, bringing the field closer to a viable treatment for dry AMD and Geographic Atrophy. As the ophthalmology community awaits data presentation at ARVO 2026, PST-611 stands out as a promising clinical candidate addressing a critical unmet need through science-driven innovation.
Source: PulseSight Therapeutics SAS press release
